Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry

Wong Y.J.Kumar R.Kumar R.Tan J.CHEN-HUA LIUHui V.W.-K.Tan S.S.JIA-HORNG KAOWong G.L.-H.Thurairajah P.H.2022-10-132022-10-1320220815-9319https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133042628&doi=10.1111%2fjgh.15918&partnerID=40&md5=fd63c690193758320d6c0375ff3423f0https://scholars.lib.ntu.edu.tw/handle/123456789/623508[SDGs]SDG3Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registryletter10.1111/jgh.15918357236452-s2.0-85133042628